Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.

[1]  W. French,et al.  Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. , 1994, Circulation.

[2]  G. Plotnick,et al.  Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. , 1994, Journal of the American College of Cardiology.

[3]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[4]  M. Packer,et al.  Role of surrogate end points in the evaluation of drugs for heart failure. , 1993, Journal of the American College of Cardiology.

[5]  J. Skoularigis,et al.  Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. , 1993, Journal of the American College of Cardiology.

[6]  D. Renlund,et al.  Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. , 1991, Circulation.

[7]  P. Broadhurst,et al.  Value of carvedilol in congestive heart failure secondary to coronary artery disease. , 1990, The American journal of cardiology.

[8]  S. G. Pollock,et al.  Usefulness of bucindolol in congestive heart failure. , 1990, The American journal of cardiology.

[9]  P. Grayburn,et al.  Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. , 1990, Circulation.

[10]  D. Renlund,et al.  Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. , 1990, The American journal of medicine.

[11]  M. Bristow,et al.  Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. , 1986, Circulation.

[12]  M. Sole,et al.  Favorable effects of pindolol in dilated cardiomyopathy. , 1986, Chest.

[13]  P A Poole-Wilson,et al.  Six minute walking test for assessing exercise capacity in chronic heart failure. , 1986, British medical journal.

[14]  R. Gunnar,et al.  Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. , 1985, Circulation.

[15]  J. Anderson,et al.  A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. , 1985, The American journal of cardiology.

[16]  J S Janicki,et al.  Cardiopulmonary exercise testing for evaluation of chronic cardiac failure. , 1985, The American journal of cardiology.

[17]  R M Gardner,et al.  "Anaerobic threshold": problems of determination and validation. , 1983, Journal of applied physiology: respiratory, environmental and exercise physiology.

[18]  M. Laks,et al.  Beta-adrenergic receptor and cyclic AMP alterations in the canine ventricular septum during long-term norepinephrine infusion: implications for hypertrophic cardiomyopathy. , 1983, Circulation.

[19]  D C Harrison,et al.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. , 1982, The New England journal of medicine.

[20]  L. Horwitz,et al.  Attenuation of Exercise Conditioning by Beta‐adrenergic Blockade , 1982, Circulation.

[21]  R. A. Johnson,et al.  Heart failure in outpatients: a randomized trial of digoxin versus placebo. , 1982, The New England journal of medicine.

[22]  H. Ikram,et al.  DOUBLE-BLIND TRIAL OF CHRONIC ORAL BETA BLOCKADE IN CONGESTIVE CARDIOMYOPATHY , 1981, The Lancet.

[23]  K. Swedberg,et al.  PROLONGATION OF SURVIVAL IN CONGESTIVE CARDIOMYOPATHY BY BETA-RECEPTOR BLOCKADE , 1979, The Lancet.

[24]  E. Varnauskas,et al.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.

[25]  Copeman Pw,et al.  LUNG CANCER AND SMOKING. , 1964, Lancet.

[26]  J. Port,et al.  Receptor pharmacology of carvedilol in the human heart. , 1992, Journal of cardiovascular pharmacology.

[27]  K. Strein,et al.  Pharmacological Profile of Carvedilol, a Compound with &bgr;‐Blocking and Vasodilating Properties* , 1987, Journal of cardiovascular pharmacology.

[28]  J. Federman,et al.  Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. , 1984, Journal of the American College of Cardiology.

[29]  T. Levine,et al.  Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. , 1981, The American journal of cardiology.